Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials

References

• Dunn JU. Uveitis. Prim Care: Clin Off Pract. 2015 Sep;42(3):305–23. Epub 2015 Jul 7. PMID: 26319340 doi: 10.1016/j.pop.2015.05.003.
   PubMed Web of Science ®Google Scholar
• McCluskey PJ. Management of chronic uveitis. BMJ. 320(7234): PMID: 10688564; PMCID: PMC1117601:555–8. 2000 Feb 26. doi: 10.1136/bmj.320.7234.555
   PubMedGoogle Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005 Sep;140(3):509–16. PMID: 16196117; PMCID: PMC8935739 doi: 10.1016/j.ajo.2005.03.057.
   PubMed Web of Science ®Google Scholar
• Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2–16. Epub 2016 Jul 28. PMID: 27467180. doi: 10.1080/09273948.2016.1196713
   PubMed Web of Science ®Google Scholar
• Al-Dhibi HA, Al-Mahmood AM, Arevalo JF. A systematic approach to emergencies in uveitis. Middle East Afr J Ophthalmol. 2014 Jul;21(3):251–258. PMID: 25100911; PMCID: PMC4123279. doi: 10.4103/0974-9233.134687
   PubMedGoogle Scholar
• Joltikov KA, Lobo-Chan AM. Epidemiology and risk factors in non-infectious uveitis: a systematic review. Front Med. 8 PMID: 34568364; PMCID: PMC8461013 2021 Sep 10: 695904. doi: 10.3389/fmed.2021.695904
   Web of Science ®Google Scholar
• Zhang Y, Amin S, Lung KI, et al. Incidence, prevalence, and risk factors of infectious uveitis and scleritis in the United States: a claims-based analysis. PLoS One. 2020 Aug 25;15(8): e0237995. PMID: 32841267; PMCID: PMC7447056. doi: 10.1371/journal.pone.0237995.
   PubMed Web of Science ®Google Scholar
• Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996 Sep;80(9):844–848. PMID: 8962842; PMCID: PMC505625. doi: 10.1136/bjo.80.9.844.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Altaweel MM, Holbrook JT, et al. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010 Apr;149(4):550–561.e10. Epub 2010 Jan 25. PMID: 20097325; PMCID: PMC2975449. doi: 10.1016/j.ajo.2009.11.019
   PubMed Web of Science ®Google Scholar
• Lee RW, Dick AD. Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye (Lond). 2012 Jan;26(1):17–28. Epub 2011 Sep 30. PMID: 21960067; PMCID: PMC3259588. doi: 10.1038/eye.2011.255
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000 Oct;130(4):492–513. PMID: 11024423. doi:10.1016/s0002-9394(00)00659-0.
   PubMed Web of Science ®Google Scholar
• Lobo-Chan AM, Joltikov K, Haseeb A, et al. A systematic review of clinical trials in uveitis: lessons learned. Ophthal Epidemiol. 2022 Oct;6:1–8. Epub ahead of print. PMID: 36204817. doi: 10.1080/09286586.2022.2131837
   Google Scholar
• Pleyer U, Pohlmann D, Kardeş E, et al. Emerging drugs for the treatment of noninfectious uveitis. Expert Opin Emerg Drugs. 2019 Sep;24(3):173–190. Epub 2019 Sep 19. PMID: 31498689. doi: 10.1080/14728214.2019.1663823
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA. 2019;322(10):936–945. doi: 10.1001/jama.2019.12618
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Hatef E, Kayen B, et al. A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmol. 2011 Jan;118(1):184–190. Epub 2010 Aug 3. PMID: 20678806. doi: 10.1016/j.ophtha.2010.03.029
   PubMed Web of Science ®Google Scholar
• Durrani K, Zakka FR, Ahmed M, et al. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol. 2011 Nov;56(6):474–510. PMID: 22117884. doi: 10.1016/j.survophthal.2011.05.003
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014;8:67–81. doi: 10.2147/BTT.S41477
   PubMedGoogle Scholar
• Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2019 May;30(3):138–150. doi: 10.1097/ICU.0000000000000562
   PubMed Web of Science ®Google Scholar
• Lin P, Suhler EB, Rosenbaum JT. The future of uveitis treatment. Ophthalmol. 2014;121(1):365–376. doi: 10.1016/j.ophtha.2013.08.029
   PubMed Web of Science ®Google Scholar
• Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007 Nov;18(6):481–486. doi: 10.1097/ICU.0b013e3282f03d42
   PubMed Web of Science ®Google Scholar
• Deaner JD, Srivastava SK, Hajj-Ali RA, et al. Recurrence rates of inflammation after switching from the originator infliximab to biosimilar infliximab-abda for noninfectious uveitis. Am J Ophthalmol. 2021;225:172–177. doi: 10.1016/j.ajo.2020.08.005
   PubMedGoogle Scholar
• Murray GM, Griffith N, Sinnappurajar P, et al. Clinical efficacy of biosimilar switch of adalimumab for management of uveitis. Ocul Immunol Inflamm. Published online Feb 21, 2023;1–5. doi: 10.1080/09273948.2023.2172591
   Web of Science ®Google Scholar
• Kumar N, Follestad T, Sen HN, et al. A systematic switch from originator infliximab to biosimilar infliximab in patients with non-infectious uveitis. Am J Ophthalmol. 2021;225:178–184. doi: 10.1016/j.ajo.2020.10.013
   PubMed Web of Science ®Google Scholar
• Levy-Clarke JD, Read R, Read RW, et al. Expert panel recommendations for the use of anti–tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmol. 2014;121(3):785–96. doi: 10.1016/j.ophtha.2013.09.048
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016Sep 17;388(10050):1183–92. Epub 2016 Aug 16. Erratum in: Lancet. 2016 Sep 17;388(10050):1160. PMID: 27542302. doi: 10.1016/S0140-6736(16)31339-3
   PubMed Web of Science ®Google Scholar
• Suhler EB, Jaffe GJ, Fortin E, et al. Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmol. 2021 Jun;128(6):899–909. Epub 2020 Nov 3. PMID: 33157077. doi: 10.1016/j.ophtha.2020.10.036
   PubMed Web of Science ®Google Scholar
• Stuart A Noninfectious uveitis. EyeNet [Internet]. 2017 Jul [cited 2023 Jun 27]. Available from: https://www.aao.org/eyenet/article/noninfectious-uveitis-3
   Google Scholar
• Fabiani C, Sota J, Rigante D, et al. Rapid and sustained efficacy of Golimumab in the treatment of multirefractory uveitis associated with Behçet’s disease. Ocul Immunol Inflamm. 2019;27(1):58–63. doi: 10.1080/09273948.2017.1351573
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Calvo-Río V, Adán A, et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators Inflamm. 2014;2014:717598. doi: 10.1155/2014/717598
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Blanco R, Santos-Gómez M, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016;46(1):95–101. doi: 10.1016/j.semarthrit.2016.03.002
   PubMed Web of Science ®Google Scholar
• Gerriets V, Goyal A, Khaddour K Tumor necrosis factor inhibitors. [ Updated 2022 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482425/
   Google Scholar
• Mehta N S, Emami-Naeini P. A review of systemic biologics and local immunosuppressive medications in uveitis. J Ophthalmic Vis Res. 17(2): PMID: 35765634; PMCID: PMC9185190:276–289. 2022 Apr 29. doi: 10.18502/jovr.v17i2.10804
   PubMed Web of Science ®Google Scholar
• Jabs DA. Immunosuppression for the uveitides. Ophthalmol. 2018 Feb;125(2):193–202. Epub 2017 Sep 20. PMID: 28942074; PMCID: PMC5794515. doi: 10.1016/j.ophtha.2017.08.007
   PubMed Web of Science ®Google Scholar
• Valdes LM, Sobrin L. Uveitis therapy: the corticosteroid options. Drugs. 2020 Jun;80(8):765–773. PMID: 32350761. doi: 10.1007/s40265-020-01314-y
   PubMed Web of Science ®Google Scholar
• Jeng KW, Fine HF, Wheatley HM, et al. Incidence of steroid-induced ocular hypertension after vitreoretinal surgery with difluprednate versus prednisolone acetate. Retina. 2014 Oct;34(10):1990–1996. PMID: 25121927. doi: 10.1097/IAE.0000000000000215
   PubMed Web of Science ®Google Scholar
• Saraiya NV, Goldstein DA. Dexamethasone for ocular inflammation. Expert Opin Pharmacother. 2011 May;12(7):1127–1131. Epub 2011 Apr 2. PMID: 21457057 doi: 10.1517/14656566.2011.571209
   PubMed Web of Science ®Google Scholar
• Kempen JH, Altaweel MM, Altaweel MM, et al. Writing committee for the multicenter uveitis steroid treatment (must) trial and follow-up study research group, association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA. 2017;317(19):1993–2005. doi: 10.1001/jama.2017.5103
   PubMed Web of Science ®Google Scholar
• Habot-Wilner Z, Noronha G, Wykoff CC. Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. Acta Ophthalmol. 2019 Aug;97(5):460–472. Epub 2019 Jan 31. PMID: 30702218 doi: 10.1111/aos.14042
   PubMed Web of Science ®Google Scholar
• Barar J, Aghanejad A, Fathi M, et al. Advanced drug delivery and targeting technologies for the ocular diseases. Bioimpacts. 2016;6(1):49–67. Epub 2016 Mar 30. PMID: 27340624; PMCID: PMC4916551. doi: 10.15171/bi.2016.07
   PubMed Web of Science ®Google Scholar
• Shulman S, Jóhannesson G, Stefánsson E, et al. Topical dexamethasone-cyclodextrin nanoparticle eye drops for non-infectious Uveitic macular oedema and vitritis - a pilot study. Acta Ophthalmol. 2015 Aug;93(5):411–415. Epub 2015 May 18. PMID: 25988730. doi: 10.1111/aos.12744
   PubMed Web of Science ®Google Scholar
• Korn T, Mitsdoerffer M, Croxford AL, et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2008;105(47):18460–18465. doi: 10.1073/pnas.0809850105
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. doi: 10.1101/cshperspect.a016295
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235–238. doi: 10.1038/nature04753
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science. 1988;241(4867):825–828. doi: 10.1126/science.3136546
   PubMed Web of Science ®Google Scholar
• Servais FA, Kirchmeyer M, Hamdorf M, et al. Modulation of the IL-6-Signaling pathway in liver cells by miRnas targeting gp130, JAK1, and/or STAT3. Mol Ther Nucleic Acids. 2019;16:419–433. doi: 10.1016/j.omtn.2019.03.007
   PubMedGoogle Scholar
• Wang SW, Sun YM. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (review). Int J Oncol. 2014;44(4):1032–1040. doi: 10.3892/ijo.2014.2259
   PubMed Web of Science ®Google Scholar
• Montero-Julian FA. The soluble IL-6 receptors: serum levels and biological function. Cell Mol Biol (Noisy-le-Grand). 2001;47(4):583–597.
   PubMed Web of Science ®Google Scholar
• Muangchant C, Pope JE. The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review. Clin Exp Rheumatol. 2013;31(2 Suppl 76):122–134.
   PubMed Web of Science ®Google Scholar
• Pignatti P, Ciapponi L, Galle P, et al. High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130. Clin Exp Immunol. 2003;131(2):355–363. doi: 10.1046/j.1365-2249.2003.02052.x
   PubMed Web of Science ®Google Scholar
• Shimamoto K, Ito T, Ozaki Y, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol. 2013;40(7):1074–1081. doi: 10.3899/jrheum.121389
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford). 2009;48(4):347–354. doi: 10.1093/rheumatology/ken489
   PubMed Web of Science ®Google Scholar
• Perez VL, Papaliodis GN, Chu D, et al. Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm. 2004;12(3):193–201. doi: 10.1080/092739490500282
   PubMed Web of Science ®Google Scholar
• Murray PI, Hoekzema R, van Haren MA, et al. Aqueous humor interleukin-6 levels in uveitis. Invest Ophthalmol Vis Sci. 1990;31(5):917–920.
   PubMed Web of Science ®Google Scholar
• Kramer M, Monselise Y, Bahar I, et al. Serum cytokine levels in active uveitis and remission. Curr Eye Res. 2007;32(7–8):669–675. doi: 10.1080/02713680701523147
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-Producing T cells. Immunity. 2006;24(2):179–189. doi: 10.1016/j.immuni.2006.01.001
   PubMed Web of Science ®Google Scholar
• Guedes MC, Borrego LM, Proença RD. Roles of interleukin-17 in uveitis. Indian J Ophthalmol. 2016 Sep;64(9):628–634. PMID: 27853008; PMCID: PMC5151150 doi: 10.4103/0301-4738.194339
   PubMed Web of Science ®Google Scholar
• Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133–1141. doi: 10.1038/ni1261
   PubMed Web of Science ®Google Scholar
• Cascão R, Moura RA, Perpétuo I, et al. Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R196. doi: 10.1186/ar3168
   PubMed Web of Science ®Google Scholar
• Mei Y, Pan F, Gao J, et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol. 2011;30(2):269–273. doi: 10.1007/s10067-010-1647-4
   PubMed Web of Science ®Google Scholar
• Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65–70. doi: 10.1136/gut.52.1.65
   PubMed Web of Science ®Google Scholar
• Wong CK, Lit LC, Tam LS, et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008;127(3):385–393. doi: 10.1016/j.clim.2008.01.019
   PubMed Web of Science ®Google Scholar
• Li J, Chen X, Liu Z, et al. Expression of Th17 cytokines in skin lesions of patients with psoriasis. J Huazhong Univ Sci Technolog Med Sci. 2007;27(3):330–332. doi: 10.1007/s11596-007-0329-1
   PubMedGoogle Scholar
• El-Asrar AM, Struyf S, Kangave D, et al. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol. 2011;139(2):177–184. doi: 10.1016/j.clim.2011.01.014
   PubMed Web of Science ®Google Scholar
• Jawad S, Liu B, Agron E, et al. Elevated serum levels of interleukin-17A in uveitis patients. Ocul Immunol Inflamm. 2013;21(6):434–439. doi: 10.3109/09273948.2013.815786
   PubMed Web of Science ®Google Scholar
• Kuiper JJ, Mutis T, de Jager W, et al. Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29–associated Birdshot Chorioretinopathy. Am J Ophthalmol. 2011;152(2):177–82.e1. doi: 10.1016/j.ajo.2011.01.031
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Sonoda KH, Miyazaki Y, et al. Differential roles for IFN- and IL-17 in experimental autoimmune uveoretinitis. Int Immunol. 2008;20(2):209–214. doi: 10.1093/intimm/dxm135
   PubMed Web of Science ®Google Scholar
• Amadi-Obi A, Yu CR, Liu X, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007;13(6):711–718. doi: 10.1038/nm1585
   PubMed Web of Science ®Google Scholar
• Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86(1):148–157. doi: 10.1016/j.jaad.2021.06.869
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. doi: 10.1038/nrd.2017.201
   PubMed Web of Science ®Google Scholar
• Kvist-Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review. Dermatol Ther. 2019;10(1):29–42. doi: 10.1007/s13555-019-00347-w
   Web of Science ®Google Scholar
• Letko E, Yeh S, Foster CS, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmol. 2015;122(5):939–948. doi: 10.1016/j.ophtha.2014.12.033
   PubMed Web of Science ®Google Scholar
• Chen M, Li X, Liu J, et al. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model. J Control Release. 2015 Apr 10;203:109–117. Epub 2015 Feb 17. PMID: 25700623. doi: 10.1016/j.jconrel.2015.02.021
   PubMed Web of Science ®Google Scholar
• Gilger BC, Abarca EM, Salmon JH, et al. Treatment of acute posterior uveitis in a porcine model by injection of triamcinolone acetonide into the suprachoroidal space using microneedles. Invest Ophthalmol Vis Sci. 2013 Apr 3;54(4): 2483–2492. PMID: 23532526. doi: 10.1167/iovs.13-11747
   PubMed Web of Science ®Google Scholar
• Yeh S, Khurana RN, Shah M, et al. PEACHTREE study investigators. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial. Ophthalmol. 2020 Jul;127(7):948–955. Epub 2020 Jan 10. PMID: 32173113. doi: 10.1016/j.ophtha.2020.01.006
   PubMed Web of Science ®Google Scholar
• Multicenter Uveitis Steroid Treatment Trial Research Group, Thorne JE, Sugar EA, Holbrook JT, et al. Periocular triamcinolone vs. Intravitreal triamcinolone vs. Intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) trial. Ophthalmol. 2019 Feb;126(2):283–295. Epub 2018 Sep 27. PMID: 30269924; PMCID: PMC6348060. doi:10.1016/j.ophtha.2018.08.021
   PubMed Web of Science ®Google Scholar
• Khurana RN, Merrill P, Yeh S, et al. Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA). Br J Ophthalmol. 2022 Aug;106(8):1139–1144. Epub 2021 Mar 12. PMID: 33712478; PMCID: PMC9340030. doi: 10.1136/bjophthalmol-2020-317560
   PubMed Web of Science ®Google Scholar
• Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmol. 2015;122(7):1375–1394. doi: 10.1016/j.ophtha.2015.03.024
   PubMed Web of Science ®Google Scholar
• Barakat MR, Wykoff CC, Gonzalez V, et al. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study. Ophthalmol Retina. 2021 Jan;5(1):60–70. Epub 2020 Aug 20. PMID: 32829027. doi: 10.1016/j.oret.2020.08.007
   PubMedGoogle Scholar
• Del Amo EM, Rimpelä AK, Heikkinen E, et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 2017;57:134–185. doi: 10.1016/j.preteyeres.2016.12.001
   PubMed Web of Science ®Google Scholar
• Kompella UB, Kadam RS, Lee VHL. Recent advances in ophthalmic drug delivery. Ther Deliv. 2010;1:435–456. doi: 10.4155/tde.10.40
   PubMedGoogle Scholar
• Krag S, Hessellund A. Topical dexamethasone-cyclodextrin microparticle eye drops for uveitic macular oedema. Acta Ophthalmol. 2014 Dec;92(8):e689–90. Epub 2014 Sep 28. PMID: 25262598 doi: 10.1111/aos.12560
   PubMed Web of Science ®Google Scholar
• Stefansson E, Loftsson T, Larsen M, et al. DX-211 study group. Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: a randomized, double-masked, vehicle-controlled study. Acta Ophthalmol. 2023 Feb;101(1):22–33. Epub 2022 Jul 18. PMID: 35848336. doi: 10.1111/aos.15215
   PubMed Web of Science ®Google Scholar
• Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731–1740. doi: 10.1016/j.intimp.2005.05.010
   PubMed Web of Science ®Google Scholar
• Actemrahcp.com [Internet]. USA: Genetech; [cited 2023 Jun 27]. Available from: https://www.actemrahcp.com/
   Google Scholar
• Sepah YJ, Sadiq MA, Chu DS, et al. Primary (month-6) outcomes of the STOP-Uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71–80. doi: 10.1016/j.ajo.2017.08.019
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020;2(3):e135–e141. doi: 10.1016/S2665-9913(20)30008-4
   PubMedGoogle Scholar
• Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and safety of Sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study. Ophthalmol. 2019;126(3):428–437. doi: 10.1016/j.ophtha.2018.09.044
   PubMed Web of Science ®Google Scholar
• Sharma S, Suhler E, Lin P, et al. A novel intravitreal anti-IL-6 monoclonal antibody for uveitic macular edema (UME): preliminary results from the phase 1 DOVETAIL study. Association for research in vision and Ophthalmology. ARVO Annual Meeting Abstract. New Orleans, LA, USA; 2023[2023 Apr 23-27].
   Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Psoriasis study group; durez P, tak PP, Gomez-Reino JJ. rheumatoid arthritis study group; Foster CS, Kim RY, Samson CM, et al. uveitis study group; Rose K, Haider A, Di padova F. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010 Oct 6;2(52):52ra72. PMID: 20926833. doi: 10.1126/scitranslmed.3001107
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmol. 2013 Apr;120(4):777–787. Epub 2013 Jan 3. PMID: 23290985. doi: 10.1016/j.ophtha.2012.09.040
   PubMed Web of Science ®Google Scholar
• Klint S, Feldwisch J, Gudmundsdotter L, et al. Izokibep: preclinical development and first-in-human study of a novel IL-17A neutralizing affibody molecule in patients with plaque psoriasis. MAbs. 2023 Jan;15(1):2209920. PMID: 37184136; PMCID: PMC10187109. doi: 10.1080/19420862.2023.2209920
   PubMed Web of Science ®Google Scholar
• Behrens F, Taylor PC, Wetzel D, et al. OP0258 IZOKIBEP (ABY-035) in PATIENTS with ACTIVE PSORIATIC ARTHRITIS – 16-WEEK RESULTS from a PHASE 2 STUDY annals of the Rheumatic diseases. Ann Rheumatic Dis. 2022;81(Suppl 1):170–171. doi: 10.1136/annrheumdis-2022-eular.536
   Google Scholar
• Durez P, Hoekema A, Huizinga T, et al. Treatment innovation for patients: a collaborative network in the Benelux and an inside view of 20 years of Galapagos. Acta Clin Belg. 2020;77(1):233–240. doi: 10.1080/17843286.2020.1812830
   PubMed Web of Science ®Google Scholar
• Van Rompaey L, Galien R, van der Aar EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013;191(7):3568–3577. doi: 10.4049/jimmunol.1201348
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [Internet]. The Netherlands: European Medicines Agency; [Cited 2023 May 25]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca
   Google Scholar
• Medscape [Internet]. USA: Medscape Ophthalmology; [Cited 2023 May 25]. Available from: https://www.medscape.com/s/viewarticle/980731
   Google Scholar
• Jo CE, Gooderham M, Beecker J. TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors. Int J Dermatol. 2022;61:139–147. doi: 10.1111/ijd.15605
   PubMed Web of Science ®Google Scholar
• Fensome A, Ambler CM, Arnold E, et al. Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). J Med Chem. 2018;61(19):8597–8612. doi: 10.1021/acs.jmedchem.8b00917
   PubMed Web of Science ®Google Scholar
• Banfield C, Scaramozza M, Zhang W, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis. J Clin Pharmacol. 2018;58:434–447. doi: 10.1002/jcph.1046
   PubMed Web of Science ®Google Scholar
• Forman SB, Pariser DM, Poulin Y, et al. TYK2/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, Double-blind, placebo-controlled trial. J Investig Dermatol. 2020;140(12):2359–2370.e5. doi: 10.1016/j.jid.2020.03.962
   PubMed Web of Science ®Google Scholar
• King B, Guttman-Yassky E, Peeva E, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus Kinase inhibitors ritlecitinib and Brepocitinib in Alopecia Areata: 24-week results. J Am Acad Dermatol. 2021;85:379–387. doi: 10.1016/j.jaad.2021.03.050
   PubMed Web of Science ®Google Scholar
• Landis MN, Arya M, Smith S, et al. Efficacy and safety of topical Brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase iib, randomized, Double-blind, vehicle-controlled, dose-ranging and Parallel-group study*. Br J Derm. 2022;187(6):878–887. doi: 10.1111/bjd.21826
   PubMed Web of Science ®Google Scholar
• Mérida S, Palacios E, Navea A, et al. New immunosuppressive therapies in uveitis treatment. Int J Mol Sci. 2015;16(8):18778–18795. doi: 10.3390/ijms160818778
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Bodaghi B, Couto C, et al. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: a review. Semin Arthritis Rheum. 2019;49(3):438–445. doi: 10.1016/j.semarthrit.2019.06.004
   PubMed Web of Science ®Google Scholar